Swedish Orphan Biovitrum AB (publ)
STO:SOBI
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
239.4
346.4
|
| Price Target |
|
We'll email you a reminder when the closing price reaches SEK.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Swedish Orphan Biovitrum AB (publ)
Swedish Orphan Biovitrum AB (publ)
Capital Expenditures
Swedish Orphan Biovitrum AB (publ)
Capital Expenditures Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Capital Expenditures | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
|
Capital Expenditures
-kr3.4B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
18%
|
CAGR 10-Years
-42%
|
|
|
Biogaia AB
STO:BIOG B
|
Capital Expenditures
-kr48.6m
|
CAGR 3-Years
-45%
|
CAGR 5-Years
-29%
|
CAGR 10-Years
N/A
|
|
|
Bonesupport Holding AB
STO:BONEX
|
Capital Expenditures
-kr8.4m
|
CAGR 3-Years
-66%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
N/A
|
|
|
Vitrolife AB
STO:VITR
|
Capital Expenditures
-kr156m
|
CAGR 3-Years
-73%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
N/A
|
|
|
Probi AB
STO:PROB
|
Capital Expenditures
-kr57.4m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-31%
|
CAGR 10-Years
-16%
|
|
|
BioArctic AB
STO:BIOA B
|
Capital Expenditures
-kr7.4m
|
CAGR 3-Years
16%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
N/A
|
|
Swedish Orphan Biovitrum AB (publ)
Glance View
Swedish Orphan Biovitrum AB (publ), often referred to as Sobi, is a biopharmaceutical company that has carved a niche in the development and commercialization of innovative treatments for rare diseases, primarily focusing on hematology, immunology, and specialty care. Founded in 2001 and headquartered in Stockholm, Sobi has garnered a reputation for its commitment to improving the lives of patients with complex medical conditions. The company's portfolio includes several key products that address unmet medical needs, particularly in areas such as hemophilia and other inherited disorders. Through strategic partnerships and acquisitions, Sobi has expanded its capabilities, bolstering its research and development pipeline while strengthening its market presence across Europe, North America, and beyond. As an investor, Sobi presents a compelling opportunity in the growing field of rare diseases, bolstered by a robust regulatory framework that often allows for expedited approval processes for groundbreaking therapies. The company’s focus on precision medicine and its dedication to patient-centric care position it well in an industry characterized by high demand and limited competition. With a solid financial foundation and a proactive approach to innovation, Sobi is poised to capture significant market share in a rapidly evolving landscape. Furthermore, with its strategic initiatives in expanding global reach and investing in next-generation therapies, Sobi exemplifies the principles of value investing by aligning long-term growth potential with the increasing need for specialized medical treatments.
See Also
What is Swedish Orphan Biovitrum AB (publ)'s Capital Expenditures?
Capital Expenditures
-3.4B
SEK
Based on the financial report for Sep 30, 2024, Swedish Orphan Biovitrum AB (publ)'s Capital Expenditures amounts to -3.4B SEK.
What is Swedish Orphan Biovitrum AB (publ)'s Capital Expenditures growth rate?
Capital Expenditures CAGR 10Y
-42%
Over the last year, the Capital Expenditures growth was 25%. The average annual Capital Expenditures growth rates for Swedish Orphan Biovitrum AB (publ) have been -9% over the past three years , 18% over the past five years , and -42% over the past ten years .
You don't have any saved screeners yet
